News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|August 9, 2024

The Challenges of PTSD Symptom Clusters

Author(s)John J. Miller, MD

John J. Miller, MD, provides an overview of the symptom clusters of PTSD and treatments that are being looked at to improve patient care.

Episodes in this series

John J. Miller, MD

EP. 1 The Evolution of PTSD Diagnosis and Treatment

John J. Miller, MD

EP. 2 MDMA-Assisted Therapy: Providing the Brain With a Necessary Boost

John J. Miller, MD

EP. 3 The Challenges of PTSD Symptom Clusters

John J. Miller, MD

EP. 4 Unmet Needs and the PTSD Treatment Pipeline

John J. Miller, MD

EP. 5 Do No Harm: Providing Guardrails for Effective PTSD Treatments

John J. Miller, MD

EP. 6 The Harms and Consequences of Untreated PTSD

PTSD

EP. 7 5 Key Take-Aways About PTSD Treatment: A Closer Look at MDMA

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

PTSD

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

May 26th 2026

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

ByAmanda Koire, MD, PhD

May 18th 2026

FDA Fast-Tracks Psychedelic Therapies for Depression, PTSD, and Alcohol Use Disorder

ByHeidi Anne Duerr, MPH

April 24th 2026

PTSD

Multilayered Trauma, One PTSD Diagnosis?

ByErica Browne,Catalina Belean, MD

March 9th 2026

psychedelic

Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD

ByKeith Jenkins, DNP, PMHNP-BC, FNP-C, AGNP-C

February 20th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

New Name, New Path for Psychiatry: The Future of the DSM

Endangered Education: Psychiatric Professional Degrees Under Attack

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy